Suppr超能文献

[住院儿童尿路感染的抗生素治疗]

[Antibiotic treatment of urinary tract infections in hospitalized children].

作者信息

Bianchetti M G, Markus-Vecerova D, Schaad U B

机构信息

Medizinische Kinderklinik, Universität Bern.

出版信息

Schweiz Med Wochenschr. 1995 Feb 11;125(6):201-6.

PMID:7871402
Abstract

From 1980 to 1991 237 patients (aged 1 week to 15 years) with moderate to severe urinary tract infection had been treated at the Department of Pediatrics University of Berne, Switzerland. Bacterial etiology, antimicrobial in vitro susceptibility tests, and drug management were retrospectively analyzed. 266 bacterial pathogens were isolated from these patients. Escherichia coli was the most frequent etiologic agent (203), followed by Enterococcus (21), Klebsiella (20), Proteus (12), Pseudomonas (6), Enterobacter (2) and Serratia (2). The overall in vitro susceptibility of these isolates was 61% for aminopenicillins, 80% for co-amoxiclav, 83% for co-trimoxazole and 92% for aminoglycosides. Aminoglycosides were ineffective in vitro only against enterococci. However, since all enterococcal strains were always sensitive to aminopenicillins, none of the pathogens was concomitantly resistant to both aminoglycosides and aminopenicillins. Parenteral therapy had been given initially in 141 patients (59%); aminopenicillin and aminoglycoside in 105, and aminopenicillin alone in 36 cases (cefuroxime instead of aminopenicillin in some patients with suspected allergy to penicillin). 96 patients (41%) were initially treated with oral antibiotics (cotrimoxazole, aminopenicillin or co-amoxiclav). The initial antimicrobial regimen had to be modified in 31 cases (13%). In children with moderate to severe urinary tract infection prompt sterilization of urine and kidneys will prevent or suppress renal tissue lesions. The in vitro susceptibility results observed in the pathogens isolated in the patients prompt us to suggest that the above mentioned goal can only be achieved by an initial regimen consisting of an aminopenicillin and an aminoglycoside compound administered parenterally.

摘要

1980年至1991年期间,瑞士伯尔尼大学儿科学系对237例(年龄从1周至15岁)中重度尿路感染患者进行了治疗。对细菌病因、抗菌药物体外敏感性试验及药物治疗情况进行了回顾性分析。从这些患者中分离出266种细菌病原体。大肠埃希菌是最常见的病原体(203例),其次是肠球菌(21例)、克雷伯菌(20例)、变形杆菌(12例)、铜绿假单胞菌(6例)、肠杆菌(2例)和沙雷菌(2例)。这些分离菌株对氨基青霉素的总体体外敏感性为61%,对阿莫西林克拉维酸为80%,对复方新诺明为83%,对氨基糖苷类为92%。氨基糖苷类仅对肠球菌体外无效。然而,由于所有肠球菌菌株对氨基青霉素始终敏感,没有病原体同时对氨基糖苷类和氨基青霉素耐药。141例患者(59%)最初接受了肠外治疗;105例使用氨基青霉素和氨基糖苷类,36例单独使用氨基青霉素(一些怀疑对青霉素过敏的患者用头孢呋辛替代氨基青霉素)。96例患者(41%)最初接受口服抗生素治疗(复方新诺明、氨基青霉素或阿莫西林克拉维酸)。31例患者(13%)的初始抗菌方案必须进行调整。对于中重度尿路感染患儿,迅速使尿液和肾脏无菌可预防或抑制肾组织损伤。在患者中分离出的病原体的体外敏感性结果促使我们提出,上述目标只能通过初始方案为肠外给予氨基青霉素和氨基糖苷类化合物来实现。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验